☆ 4.6 Article

Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer's disease and frontotemporal dementia

ALZHEIMERS RESEARCH & THERAPY (2023)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Fluid markers of synapse degeneration in synucleinopathies

Alba Cervantes Gonzalez et al.

Summary: The abnormal accumulation of alpha-synuclein in the brain is a common feature of Parkinson's disease (PD), PD dementia (PDD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Synapse degeneration is the crucial neuropathological event in these synucleinopathies and the neuropathological correlate of connectome dysfunction. A marker of synapse degeneration that can correlate with measures of cognitive or motor impairment could serve as a more objective, surrogate biomarker of the core clinical features of these diseases. This review discusses candidate biomarkers of synapse degeneration in PD, PDD, DLB, and MSA patient-derived biofluids and their relevance to alpha-synuclein-mediated synapse degeneration mechanisms.

JOURNAL OF NEURAL TRANSMISSION (2022)

Add to Collection

Article Neurosciences

Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration

Alba Cervantes Gonzalez et al.

Summary: The study found an association between synaptic proteins and pathological burden and cognitive performance in frontotemporal lobar degeneration (FTLD) patients. These synaptic panels have the potential to differentiate FTLD neuropathologic subtypes and serve as surrogate markers for cognitive performance in future clinical trials.

MOLECULAR NEURODEGENERATION (2022)

Add to Collection

Article Clinical Neurology

Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease

Pia Kivisakk et al.

Summary: This study measured the levels of synaptic proteins in cerebrospinal fluid (CSF) and found that these proteins could potentially serve as biomarkers for cognitive decline in Alzheimer's disease (AD). The levels of the synaptic proteins were higher in AD patients compared to those with other neurodegenerative diseases and healthy controls, but were not specific to AD and could also be present in cases with inflammatory or vascular disorders.

ALZHEIMERS RESEARCH & THERAPY (2022)

Add to Collection

Article Psychiatry

Glutamate receptor 4 as a fluid biomarker for the diagnosis of psychiatric disorders

Nerea Gomez de San Jos et al.

Summary: Psychiatric disorders, especially in early stages, are often underreported, and there is currently no definitive biomarker for diagnosis. This study established a novel ELISA method to analyze GluR4 levels in cerebrospinal fluid samples, and found that GluR4 may serve as a potential diagnostic biomarker for major depressive disorder. The findings contribute to the clinical application of GluR4 as a diagnostic biomarker for psychiatric disorders and enhance the understanding of their pathophysiological mechanisms.

JOURNAL OF PSYCHIATRIC RESEARCH (2022)

Add to Collection

Article Biochemistry & Molecular Biology

A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration

Shreyasee Das et al.

Summary: This study describes a novel Nf-L enzyme-linked immunosorbent assay (ELISA) with well-defined specificity and epitopes, which can accurately measure Nf-L analytes in cerebrospinal fluid and discriminate different diseases in clinical diagnosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia

Aitana Sogorb-Esteve et al.

Summary: The study identified differential synaptic impairment in genetic forms of frontotemporal dementia, with MAPT mutation carriers showing abnormalities in multiple measures, while changes in neuronal pentraxins were observed only in GRN and C9orf72 mutation groups. These findings suggest that synaptic dysfunction markers may play different roles in the disease progression among carriers of different mutations.

ALZHEIMERS RESEARCH & THERAPY (2022)

Add to Collection

Article Cell Biology

CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels

Marta del Campo et al.

Summary: This study identifies specific dysregulated CSF proteins along the AD continuum, reflecting the multifactorial nature of disease progression. Some of these dysregulated proteins can be used as biomarkers for the diagnosis and clinical trials of AD.

NATURE AGING (2022)

Add to Collection

Article Geriatrics & Gerontology

Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia

Eline A. J. Willemse et al.

Summary: The study found that CSF Ng concentrations differ among AD, non-AD, and control groups, but are not associated with tissue Ng concentrations. CSF Ng is a general biomarker for synaptic degeneration, strongly correlated with CSF tau, but without added value for the differential diagnosis of AD.

NEUROBIOLOGY OF AGING (2021)

Add to Collection

Review Clinical Neurology

Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders

Simon Ducharme et al.

BRAIN (2020)

Add to Collection

Article Neurosciences

Contribution of CSF biomarkers to early-onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures

Neus Falgas et al.

HUMAN BRAIN MAPPING (2020)

Add to Collection

Article Clinical Neurology

Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia

Emma L. van der Ende et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)

Add to Collection

Article Multidisciplinary Sciences

Different regions of synaptic vesicle membrane regulate VAMP2 conformation for the SNARE assembly

Chuchu Wang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research

Nathalie Percie du Sert et al.

PLOS BIOLOGY (2020)

Add to Collection

Article Neurosciences

End Stage Clinical Features and Cause of Death of Behavioral Variant Frontotemporal Dementia and Young-Onset Alzheimer's Disease

Marie-Paule E. van Engelen et al.

JOURNAL OF ALZHEIMERS DISEASE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Comprehensive Review on Alzheimer's Disease: Causes and Treatment

Zeinab Breijyeh et al.

MOLECULES (2020)

Add to Collection

Article Medical Laboratory Technology

Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?

Alberto Lleo et al.

CLINICA CHIMICA ACTA (2019)

Add to Collection

Article Biochemical Research Methods

Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid

Alberto Lleo et al.

MOLECULAR & CELLULAR PROTEOMICS (2019)

Add to Collection

Article Clinical Neurology

CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia

Mica T. M. Clarke et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

Add to Collection

Article Biochemical Research Methods

A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease

Gunnar Brinkmalm et al.

PROTEOMICS CLINICAL APPLICATIONS (2018)

Add to Collection

Review Neurosciences

Amsterdam Dementia Cohort: Performing Research to Optimize Care

Wiesje M. van der Flier et al.

JOURNAL OF ALZHEIMERS DISEASE (2018)

Add to Collection

Review Medicine, General & Internal

Biomarkers for Alzheimer's disease: current status and prospects for the future

K. Blennow et al.

JOURNAL OF INTERNAL MEDICINE (2018)

Add to Collection

Review Clinical Neurology

Current state of Alzheimer's fluid biomarkers

Jose Luis Molinuevo et al.

ACTA NEUROPATHOLOGICA (2018)

Add to Collection

Review Clinical Neurology

Biomarkers for Alzheimer's Disease Diagnosis

Vasileios Mantzavinos et al.

CURRENT ALZHEIMER RESEARCH (2017)

Add to Collection

Article Clinical Neurology

Increased CSF neurogranin concentration is specific to Alzheimer disease

Henrietta Wellington et al.

NEUROLOGY (2016)

Add to Collection

Article Clinical Neurology

A practical guide to immunoassay method validation

Ulf Andreasson et al.

FRONTIERS IN NEUROLOGY (2015)

Add to Collection

Review Neurosciences

Synapse Loss in Dementias

Ryan Clare et al.

JOURNAL OF NEUROSCIENCE RESEARCH (2010)

Add to Collection

Article Psychology, Mathematical

G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences

Franz Faul et al.

BEHAVIOR RESEARCH METHODS (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.